{"preliminary_commentary":{"by_channel":{"x_thread":624,"bluesky_thread":12,"youtube":8,"podcast":3,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03937635\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"DETER-SMM","nct_id":"NCT03937635","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=deter-smm-nct03937635. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of courses 7-24. Patients also receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 in courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm I (daratumumab, lenalidomide, dexamethasone)","type":"EXPERIMENTAL"},{"description":"Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm II (lenalidomide, dexamethasone)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"conditions":["Smoldering Plasma Cell Myeloma"],"enrollment":{"count":288,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Daratumumab","otherNames":["Anti-CD38 Monoclonal Antibody","Darzalex","HuMax-CD38","JNJ-54767414"],"type":"BIOLOGICAL"},{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Fluorodelta","Fortecortin","Gammacorten","Hexadecadrol","Hexadrol","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","Visumetazone"],"type":"DRUG"},{"name":"Lenalidomide","otherNames":["CC-5013","CC5013","CDC 501","Revlimid"],"type":"DRUG"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-08-19","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"From randomization to death due to any cause, or censored at date last known alive, assessed up to 15 years"},{"measure":"Functional Assessment of Cancer Therapy-General (FACT-G) score","timeFrame":"Baseline to 24 cycles of treatment (each cycle is 28 days)"}],"references":[],"start_date":{"date":"2019-09-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","url":"https://clinicaltrials.gov/study/NCT03937635"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/deter-smm-nct03937635"}